// App-Quantinova.ai

518 : Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab weekly paclitaxel in HER2+/HR- early breast cancer (EBC).

Researchers

Presenter

  • Ulrike Nitz

Principal Investigators

  • Matthias Christgen

  • Eva-Maria Grischke

  • Doris Augustin

  • Sherko Kummel

  • Michael Wilhelm Braun

  • Jochem Potenberg

  • Andreas Kohls

  • Katja Krauss

  • Andrea Stefek

  • Claudia Schumacher

  • Helmut Forstbauer

  • Toralf Reimer

  • Hans Holger Fischer

  • Cornelia Liedtke

  • Rachel Wuerstlein

  • Hans Heinrich Kreipe

  • Nadia Harbeck

Medical Centers

  • Evangelic Hospital Bethesda, Moenchengladbach, Germany

  • West German Study Group, Moenchengladbach, Germany

  • Hannover Medical School, Hannover, Germany

  • Universitts-Frauenklinik Tubingen, Tubingen, Germany

  • Klinikum Deggendorf, Deggendorf, Germany

  • Department of Senology / Breast Care Center, Kliniken Essen Mitte, Essen, Germany

  • Rotkreuzklinikum, Munich, Germany

  • Department of Hematology, Waldkrankenhaus Spandau, Berlin, Germany

  • Ev. Krankenhaus Ludwigsfelde-Teltow, Ludwigsfelde-Teltow, Germany

  • Uniklinik RWTH Aachen, Aachen, Germany

  • Johanniter Krankenhaus, Genthin-Stendal, Germany

  • St. Elisabeth Hospital Koln-Hohenlind, Cologne, Germany

  • Praxisnetzwerk Hamatologie / intern. Onkologie, Troisdorf, Germany

  • University Hospital Gynecology and Policlinic Rostock, Rostock, Germany

  • Ev. Kliniken Gelsenkirchen, Gelsenkirchen, Germany

  • University of Schleswig-Holstein Campus Luebeck, Luebeck, Germany

  • University of Munich, Munich, Germany

  • Brustzentrum der Universitat Munchen (LMU), Munich, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

  • Paclitaxel

  • Pertuzumab

Outcome

  • Unknown

Study Design

  • Randomized

  • Non Inferiority

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved